development and in vitro-in vivo evaluation of controlled release matrix tablets of desvenlafaxine发展和vitro-in体内评价控释矩阵desvenlafaxine的平板电脑.pdfVIP

Pharmacology Pharmacy, 2012, 3, 15-19 15 /10.4236/pp.2012.31003 Published Online January 2012 (http://www.SciRP.org/journal/pp) Development and in Vitro-in Vivo Evaluation of Controlled Release Matrix Tablets of Desvenlafaxine 1 2* Shashidhar Reddy Dodda , Prakash Rao Boggrapu 1Department of Pharmacology, Bioneeds Preclinical Services, Bangalore, India; 2Department of Pharmaceutics, Karnataka College of Pharmacy, Bangalore, India. * Email: bprao_1111@ Received October1 14th, 2011; revised November 20th, 2011; accepted December 16th, 2011 ABSTRACT The objective of this investigation was to prepare extended release tablet containing matrix granules of Desvenlafaxine succinate monohydrate and to study its in vitro release and in vivo absorption. The design of dosage form was per- formed by choosing hydrophilic hydroxypropyl methyl cellulose (HPMC K100M), sodium carboxyl methyl cellulose (Blanose), microcrystalline cellulose (MCC) and lactose monohydrate polymers as matrix builders and polyvinyl py- rolidine (Kollidon K30) as granulating polymers. Granules were prepared by composing drug with HPMC K100M, so- dium CMC, MCC and lactose monohydrate by spray drying method. Optimized formulation of Desvenlafaxine succi- nate monohydrate was formed by using 20% HPMC K100M, 26.6% MCC, 6.6% of sodium CMC (Blanose), 13.3% of lactose monohydrate and 5% ratio of Kollidon K30 as binder. Tablets were compressed with free flowing optimized granules of uniform drug content. This extended the release period up to 24 h in vitro study. Similarity factor and mean dissolution time were also reported to compare various dissolution profiles. The network formed by HPMC, MCC and Blanose had been coupled satisfactorily with the controlled resistance. Biopharmaceutica